Cantargia – executive interview

Published on 26 May 2021

Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. Its lead asset nadunolimab (CAN04) is being investigated as a treatment for several types of solid tumours across a broad programme, the most advanced being a Phase IIa CANFOUR trial for pancreatic cancer and non-small cell lung cancer. CAN10 is being developed for systemic sclerosis and myocarditis, with clinical development expected to start in early 2022.

In this video, the company’s chief executive officer Göran Forsberg provides an update on R&D progress, including a summary of the promising results Cantargia recently reported from the pancreatic cancer arm of the CANFOUR trial.

Share this with friends and colleagues